Don't forget Will Rodger's advice "Buy good stock".
He went on to say if it goes up, good, if it goes down, better, buy more. Remember you already determined it was a good stock.
By the way, for those waiting for Missling to discuss the data, as I understand it the data has been submitted to a Journal for peer review. Beyond what's said in top line data statements companies don't discuss the data until it's undergone peer review by either being published in a peer reviewed Journal, or presented at a major technical conference where it's peer reviewed. If that's not yet happened, Missling is acting no differently than the CEO's of other similar companies.
It's sad, but after trials end and the data's quantified it often takes many months before it is peer reviewed. Many conferences require Abstract submissions many months before the actual conference, so while the conference may be months after the trial concluded, an abstract couldn't be submitted in time so the next appropriate conference may be the first where it can be presented. Journal peer reviews also often take many months, and no telling how many revisions, but eventually they happen. It's probably been six months of more since a preliminary submission to Nature was somehow leaked on NWBO, the article is yet to be published. The company has no control of how long these things take to happen.
Gary